Amarin (AMRN) News Today $19.90 +1.06 (+5.63%) As of 11:09 AM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock AMRN Latest News All Sources Trusted Sources MarketBeat Barchart Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent October 2025 September 2025 August 2025 July 2025 June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 Time Period Head-To-Head Review: Fortress Biotech (NASDAQ:FBIO) & Amarin (NASDAQ:AMRN)October 5 at 3:43 AM | americanbankingnews.comAmarin (NASDAQ:AMRN) Stock Passes Above 200 Day Moving Average - What's Next?September 30, 2025 | americanbankingnews.comAmarin (NASDAQ:AMRN) Shares Cross Above 200-Day Moving Average - Here's What HappenedSeptember 30, 2025 | marketbeat.comAmarin: Vascepa's Global Pivot From U.S. Squeeze To International BoomSeptember 29, 2025 | seekingalpha.comLCM Capital Management Inc Sells 815,348 Shares of Amarin Corporation PLC $AMRNSeptember 22, 2025 | marketbeat.comAcadian Asset Management LLC Boosts Holdings in Amarin Corporation PLC $AMRNSeptember 17, 2025 | marketbeat.comAmarin (NASDAQ:AMRN) Stock Price Crosses Above 200 Day Moving Average - Should You Sell?September 14, 2025 | marketbeat.comAmarin (NASDAQ:AMRN) Stock Passes Above 200-Day Moving Average - Should You Sell?September 6, 2025 | marketbeat.comIonis upgraded at BMO Capital Markets after data for lipid-lowering agentSeptember 3, 2025 | msn.comAmarin stock rises after ESC Congress data on VASCEPA mechanismSeptember 2, 2025 | investing.comAmarin Highlights Key Data Providing Mechanistic Insights into Eicosapentaenoic Acid (EPA) at ESC 2025August 31, 2025 | globenewswire.comNew REDUCE-IT® Analyses Presented at ESC 2025 Include Data Showing VASCEPA®/VAZKEPA® (Icosapent Ethyl) Therapy Resulted in 9% Fewer Total Hospitalizations & Reduces ...August 30, 2025 | finance.yahoo.comNew REDUCE-IT® Analyses Presented at ESC 2025 Include Data Showing VASCEPA®/VAZKEPA® (Icosapent Ethyl) Therapy Resulted in 9% Fewer Total Hospitalizations & Reduces Cardiovascular Disease Risk in Certain High-Risk Patient SubgroupsAugust 30, 2025 | globenewswire.comWe're Not Worried About Amarin's (NASDAQ:AMRN) Cash BurnAugust 29, 2025 | finance.yahoo.comZacks Research Downgrades Amarin (NASDAQ:AMRN) to HoldAugust 29, 2025 | marketbeat.comAmarin Corporation PLC $AMRN Shares Acquired by Stonepine Capital Management LLCAugust 26, 2025 | marketbeat.comAmarin announces upcoming presentations at ESC Congress 2025August 25, 2025 | msn.comNew Analyses from REDUCE-IT® and EPA Mechanistic Data to be Presented at the European Society of Cardiology (ESC) Congress 2025August 25, 2025 | globenewswire.comAmarin (NASDAQ:AMRN) Share Price Passes Above 200 Day Moving Average - What's Next?August 23, 2025 | marketbeat.comAmarin (NASDAQ:AMRN) Stock Price Crosses Above 200 Day Moving Average - Here's What HappenedAugust 14, 2025 | marketbeat.comLCM Capital Management Inc Has $385,000 Position in Amarin Corporation PLC (NASDAQ:AMRN)August 6, 2025 | marketbeat.comAmarin (NASDAQ:AMRN) Stock Rating Upgraded by Wall Street ZenAugust 3, 2025 | marketbeat.comAmarin (NASDAQ:AMRN) Issues Quarterly Earnings ResultsAugust 2, 2025 | marketbeat.comZacks Research Analysts Cut Earnings Estimates for AmarinAugust 1, 2025 | marketbeat.comAmarin (NASDAQ:AMRN) Stock Price Crosses Above 200 Day Moving Average - What's Next?July 31, 2025 | marketbeat.comAmarin Corporation plc (AMRN) Q2 2025 Earnings Call TranscriptJuly 30, 2025 | seekingalpha.comAmarin Reports Second Quarter 2025 Financial ResultsJuly 30, 2025 | globenewswire.comAmarin Q2 2025 Earnings PreviewJuly 29, 2025 | msn.comAMRN - Amarin Corp PLC ADR Key Metrics - MorningstarJuly 25, 2025 | morningstar.comMAmarin to Report Second Quarter 2025 Financial Results and Host Conference Call on July 30, 2025July 23, 2025 | globenewswire.comAmarin (AMRN) Expected to Announce Quarterly Earnings on WednesdayJuly 23, 2025 | marketbeat.comAmarin Corporation PLC (NASDAQ:AMRN) Stock Holdings Lowered by OneDigital Investment Advisors LLCJuly 12, 2025 | marketbeat.comAmarin (NASDAQ:AMRN) Share Price Crosses Above 200-Day Moving Average - What's Next?July 8, 2025 | marketbeat.comWaterfront Wealth Inc. Has $1.13 Million Stock Holdings in Amarin Corporation PLC (NASDAQ:AMRN)June 29, 2025 | marketbeat.comWhat is Zacks Research's Estimate for Amarin Q3 Earnings?June 29, 2025 | marketbeat.comAmarin (AMRN) Soars 27.3%: Is Further Upside Left in the Stock? - NasdaqJune 27, 2025 | nasdaq.comAmarin (NASDAQ:AMRN) Given New $12.00 Price Target at The Goldman Sachs GroupJune 25, 2025 | marketbeat.comAmarin, Recordati Ink Exclusive License, Supply Deal to Commercialize VazkepaJune 24, 2025 | marketwatch.comAmarin Announces Exclusive License and Supply Agreement with Recordati to Commercialize VAZKEPA® (Icosapent Ethyl) in EuropeJune 24, 2025 | finance.yahoo.comAmarin Stock Surges 11% After $25 Million Licensing Deal with RecordatiJune 24, 2025 | msn.comAmarin inks licensing deal with Recordati for lead drug VazkepaJune 24, 2025 | msn.comRECORDATI ANNOUNCES EXCLUSIVE LICENSING & SUPPLY AGREEMENT WITH AMARIN TO COMMERCIALIZE VAZKEPA® IN EUROPEJune 24, 2025 | globenewswire.comAmarin (NASDAQ:AMRN) Shares Cross Above Two Hundred Day Moving Average - Should You Sell?June 24, 2025 | marketbeat.comAmarin (NASDAQ:AMRN) Stock Passes Above Two Hundred Day Moving Average - Here's What HappenedJune 14, 2025 | marketbeat.comAmarin Is A Sell Despite The Large Cash BalanceJune 6, 2025 | seekingalpha.comZacks Research Has Positive Estimate for Amarin Q2 EarningsJune 6, 2025 | marketbeat.comShort Interest in Amarin Co. plc (NASDAQ:AMRN) Grows By 18.3%June 4, 2025 | marketbeat.comAMRN Amarin Corporation plcJune 1, 2025 | seekingalpha.comZacks Research Issues Positive Estimate for Amarin EarningsMay 31, 2025 | marketbeat.comWhat’s Trending On InvestorshubMay 27, 2025 | msn.com Get Amarin News Delivered to You Automatically Sign up to receive the latest news and ratings for AMRN and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. AMRN Media Mentions By Week AMRN Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. AMRN News Sentiment▼0.720.54▲Average Medical News Sentiment AMRN News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. AMRN Articles This Week▼42▲AMRN Articles Average Week Get the Latest News and Ratings for AMRN and Related Stocks Enter your email address to receive the latest news and analysts' ratings for Amarin and its competitors. Sign Up View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. Related Companies and Tools Related Companies Stoke Therapeutics News Xeris Biopharma News Zymeworks News Amylyx Pharmaceuticals News Sionna Therapeutics News Tilray Brands News Pharvaris News Amphastar Pharmaceuticals News Evotec News atai Life Sciences News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:AMRN) was last updated on 10/6/2025 by MarketBeat.com Staff From Our Partners"I'm risking my reputation on this"My prediction: Q4 2025 won't just be another seasonal crypto pump. It will be the quarter that sparks a crypto...Crypto 101 Media | SponsoredNvidia CEO Makes First Ever Tesla AnnouncementWhile headlines focus on Tesla’s car sales, tech analyst Jeff Brown says the real story is Tesla’s role in a $...Brownstone Research | SponsoredGet my No. 1 gold stock nowGold recently broke past $3,800 per ounce – setting yet another new all-time high. And Wall Street banks sa...Stansberry Research | SponsoredWall Street legend: “Sell this A.I. stock now”Whats next after AI? Hidden AI. "Hidden AI" could soon be the biggest investment trend of 2025.Chaikin Analytics | SponsoredThe next wave of AI fortunes may come from NVIDIA’s secret supplier.Bloomberg says AI is a $50 trillion revolution. And at the center of it… isn't NVIDIA. It's a tiny suppl...Behind the Markets | SponsoredURGENT: The Market's 3 Red Flags Are FlashingHere’s the uncomfortable truth: The smartest investors in the world are already preparing for a crash befor...StockEarnings | SponsoredGold surges past $3,600 … but this has beat gold by 1,000xGold has surged past $3,600 an ounce — up 45% in the past year — but one veteran metals analyst says the real ...Weiss Ratings | SponsoredAn $8 trillion-dollar discovery 17,000 ft underwater A strange rock pulled from the ocean floor may hold the key to a $16 trillion resource boom. Inside it: materi...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Amarin Corporation PLC Please log in to your account or sign up in order to add this asset to your watchlist. Share Amarin With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
